ND-340 is under clinical development by Nang Kuang Pharmaceutical and currently in Phase I for Post-Operative Pain. According to GlobalData, Phase I drugs for Post-Operative Pain have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ND-340’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ND-340 overview

ND-340 is under development for the treatment of post-operative analgesia in patients with total knee arthroplasty (TKA). It is an extended release formulation, administered through parenteral route as suspension.

Nang Kuang Pharmaceutical overview

Nang Kuang Pharmaceutical (Nang Kuang) is a pharmaceutical company that produces injectables. The company’s product includes large volume parenterals, lyophilized injection, aseptic parenterals, pre-filled syringe, tablets, capsules, topical products and oral suspensions. Its products are used in the therapeutic areas of cardiovascular, gastrointestinal, nervous system, blood, musculo-skeletal, respiratory, dermatology, genito-urinary and others. Nang Kuang carries out co-marketing arrangements with many pharmaceutical companies in the US and Europe. It offers various hospital solution including electrolyte solution, ringer lactate solution, sodium chloride solution, sterile water, carbohydrate and electrolyte solution, amino-acid solution and nephro amino-acid solution, among others. Nang Kuang is headquartered in Tainan, Taiwan.

For a complete picture of ND-340’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.